Pascal and Francis Bibliographic Databases

Help

Search results

Your search

is.\*:("1359-6446")

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 1608

  • Page / 65
Export

Selection :

  • and

Abiraterone acetate: redefining hormone treatment for advanced prostate cancerPEZARO, Carmel J; MUKHERJI, Deborah; DE BONO, Johann S et al.Drug discovery today. 2012, Vol 17, Num 5-6, pp 221-226, issn 1359-6446, 6 p.Article

Better compounds faster: the development and exploitation of a desktop predictive chemistry toolkitCUMMING, John G; WINTER, Jon; POIRRETTE, Andrew et al.Drug discovery today. 2012, Vol 17, Num 17-18, pp 923-927, issn 1359-6446, 5 p.Article

Bridging solubility between drug discovery and developmentLI DI; FISH, Paul V; MANO, Takashi et al.Drug discovery today. 2012, Vol 17, Num 9-10, pp 486-495, issn 1359-6446, 10 p.Article

Can we vaccinate against depression?ROOK, Graham A. W; RAISON, Charles L; LOWRY, Christopher A et al.Drug discovery today. 2012, Vol 17, Num 9-10, pp 451-458, issn 1359-6446, 8 p.Article

Contact lenses in ocular therapeuticsGUPTA, Himanshu; AQIL, Mohammed.Drug discovery today. 2012, Vol 17, Num 9-10, pp 522-527, issn 1359-6446, 6 p.Article

Evidence-based approach to assess passive diffusion and carrier-mediated drug transportLI DI; ARTURSSON, Per; LENNERNÄS, Hans et al.Drug discovery today. 2012, Vol 17, Num 15-16, pp 905-912, issn 1359-6446, 8 p.Article

Fluorine local environment: from screening to drug designVULPETTI, Anna; DALVIT, Claudio.Drug discovery today. 2012, Vol 17, Num 15-16, pp 890-897, issn 1359-6446, 8 p.Article

Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agentsCOSTANTINO, Luca; BORASCHI, Diana.Drug discovery today. 2012, Vol 17, Num 7-8, pp 367-378, issn 1359-6446, 12 p.Article

Microtissue size and hypoxia in HTS with 3D culturesASTHANA, Amish; KISAALITA, William S.Drug discovery today. 2012, Vol 17, Num 15-16, pp 810-817, issn 1359-6446, 8 p.Article

Monoclonal antibodies for chronic refractory asthma and pipeline developmentsPOLOSA, Riccardo; CASALE, Thomas.Drug discovery today. 2012, Vol 17, Num 11-12, pp 591-599, issn 1359-6446, 9 p.Article

Network medicine in drug design: implications for neuroinflammationGHOSH, Sourish; BASU, Anirban.Drug discovery today. 2012, Vol 17, Num 11-12, pp 600-607, issn 1359-6446, 8 p.Article

Open PHACTS: semantic interoperability for drug discoveryWILLIAMS, Antony J; HARLAND, Lee; MONS, Barend et al.Drug discovery today. 2012, Vol 17, Num 21-22, pp 1188-1198, issn 1359-6446, 11 p.Article

Outsourcing drug discovery to India and China: from surviving to thrivingSUBRAMANIAM, Swaminathan; DUGAR, Sundeep.Drug discovery today. 2012, Vol 17, Num 19-20, pp 1055-1058, issn 1359-6446, 4 p.Article

Rare disease patient groups as clinical researchersPOLICH, Ginger R.Drug discovery today. 2012, Vol 17, Num 3-4, pp 167-172, issn 1359-6446, 6 p.Article

Stem cell technology for drug discovery and developmentHOOK, Lilian A.Drug discovery today. 2012, Vol 17, Num 7-8, pp 336-342, issn 1359-6446, 7 p.Article

Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?ALAMA, Angela; ORENGO, Anna Maria; FERRINI, Silvano et al.Drug discovery today. 2012, Vol 17, Num 9-10, pp 435-442, issn 1359-6446, 8 p.Article

Targeting mutant huntingtin for the development of disease-modifying therapyAPPL, Thomas; KALTENBACH, Linda; LO, Donald C et al.Drug discovery today. 2012, Vol 17, Num 21-22, pp 1217-1223, issn 1359-6446, 7 p.Article

The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease'T HART, Bert A; ABBOTT, David H; NAKAMURA, Katsuki et al.Drug discovery today. 2012, Vol 17, Num 21-22, pp 1160-1165, issn 1359-6446, 6 p.Article

Translational semantics and infrastructure: another search for the emperor's new clothes?MULLANE, Kevin; WILLIAMS, Michael.Drug discovery today. 2012, Vol 17, Num 9-10, pp 459-468, issn 1359-6446, 10 p.Article

Ultra-adaptable nanovesicular systems: a carrier for systemic delivery of therapeutic agentsKUMAR, Ajay; PATHAK, Kamla; BALI, Vikas et al.Drug discovery today. 2012, Vol 17, Num 21-22, pp 1233-1241, issn 1359-6446, 9 p.Article

Decision theory and the evaluation of risks and benefits of clinical trialsBERNABE, Rosemarie D. C; THIEL, Ghislaine J. M. W. Van; RAAIJMAKERS, Jan A. M et al.Drug discovery today. 2012, Vol 17, Num 23-24, pp 1263-1269, issn 1359-6446, 7 p.Article

Rethinking leadership in drug discovery projectsSCHNEIDER, Andreas; ERDEN, Zeynep; WIDMER, Hans et al.Drug discovery today. 2012, Vol 17, Num 23-24, pp 1258-1262, issn 1359-6446, 5 p.Article

Structural mass spectrometry in biologics discovery: advances and future trendsJINGJIE MO; TYMIAK, Adrienne A; GUODONG CHEN et al.Drug discovery today. 2012, Vol 17, Num 23-24, pp 1323-1330, issn 1359-6446, 8 p.Article

A generic operational strategy to qualify translational safety biomokersMATHEIS, Katja; LAURIE, David; GOEPFERT, Jens et al.Drug discovery today. 2011, Vol 16, Num 13-14, pp 600-608, issn 1359-6446, 9 p.Article

Characteristics of orphan drug applicationsthat fail to achieve marketing approval in the USAHEEMSTRA, Harald E; LEUFKENS, Hubert G. M; CHANNING RODGERS, R. P et al.Drug discovery today. 2011, Vol 16, Num 1-2, pp 73-80, issn 1359-6446, 8 p.Article

  • Page / 65